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Abstract (184 words) 
High grade serous ovarian cancer (HGSOC) is the most frequent type of ovarian cancer. Most 
patients have primary response to platinum-based chemotherapy but frequently relapse, which 
leads to patient death. A lack of well documented and characterized patient-derived HGSOC cell 
lines is so far a major barrier to define tumor specific therapeutic targets and to study the 
molecular mechanisms underlying disease progression. We established 34 patient-derived 
HGSOC cell lines and characterized them at cellular and molecular level. Particularly, we 
demonstrated that a cancer-testis antigen PRAME and Estrogen Receptor could serve as 
therapeutic targets. Notably, data from the cell lines did not demonstrate acquired resistance due 
to tumor recurrence that matched with clinical observations. Finally, we presented that all 
HGSOC had no or very low CDKN1A (p21) expression due to loss of wild-type TP53, suggesting 
that loss of cell cycle control is the determinant for tumorigenesis and progression. In conclusion, 
patient-derived cell lines reveal that PRAME is a potential tumor specific therapeutic target in 
HGSOC and counteracting the down-regulation of p21 caused by loss of wild-type TP53 might 
be the key to impede disease progression.  
Key words: acquired platinum resistance; PRAME; tumor specific antigen; TP53; p21 down-
regulation
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1. Introduction  
Epithelial ovarian cancer (EOC) is a rare disease with a worldwide incidence and mortality of 
240000 and 150000, respectively [1]. 75% of EOC are high grade serous ovarian cancers 
(HGSOC) that are often diagnosed at advanced stage. Standard of care includes debulking 
surgery and platinum-based therapy. Most patients show primary response; however the vast 
majority relapses with resistant disease, which is defined as acquired resistance. Tumor cell 
proliferation cannot be controlled and patients die because of disease progression. The 5-year 
survival rate of patients with advanced HGSOC is below 40%. Resistance is considered the major 
course of the patients’ death [2]. In addition, platinum-based drugs kill large numbers of non-
tumor cells, dramatically reducing patients’ quality of life [3]. In order to improve ovarian cancer 
treatment, tumor specific targets have to be defined for the development of more efficient and 
less toxic therapies. 
At the molecular level, common features of HGSOC include TP53 mutations (96%) and loss of 
homologous recombination repair (HRR) due to mutational or epigenetic inactivation of the 
BRCA1/2 or other HRR genes [4]. Aside from these common traits, HGSOCs are highly 
heterogeneous with large amounts of copy number changes and chromosomal rearrangements. 
The genetic instability and the loss of functional p53 and BRCA1/2 have a direct consequence of 
higher number of mutations in tumor cells.  
To better understand the mechanisms underlying the resistance of HGSOC, well characterized 
experimental models representing the cellular and genetic backgrounds of HGSOC are essential. 
Unfortunately, by comparing copy number changes, mutations and mRNA profiles with tumors, 
it was discovered that the cell lines historically used for ovarian cancer research were most 
unlikely to be representative of HGSOC [5, 6]. For this reason, several groups including 
ourselves have previously attempted to establish HGSOC cell lines [6-11]. The number of the 
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cell lines generated from these studies is rather low and with no systematic molecular analyses. 
The lack of linked clinical data about the donors is also a drawback to understand the impact of 
cellular and molecular characteristics on disease progression [12]. 
To address this challenge, we established 34 cell lines from 23 HGSOC patients and analyzed the 
acquired resistance in these tumors and the molecular mechanisms of disease progression. 
Furthermore, we investigated potential therapeutic targets using these models and validated the 
results using RNA sequencing data from 66 paired primary and recurrent HGSOC tumors 
published in a previous study [13]. The cell line models reveal that a cancer-testis antigen 
PRAME is a potential therapeutic target for HGSOC and the down regulation of p21 caused by 
the loss of wild-type TP53 is the most important event for disease progression.  
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2. Materials and methods 
2.1. Establishing and maintaining HGSOC cell lines and primary mesothelial cell culture 
The methods of establishing and maintaining cell lines were published previously [11].  For 
tumor tissues, we abandoned the previous enzymatic digestion because of a very low success rate 
and used a cell scraper to release the tumor cells, which were collected by centrifugation. In some 
ascites, many mesothelial cells grew quickly covering the surface between tumor cell clusters in 
the culture flasks at the beginning passages. They detached very quickly upon trypsinization 
(<2mins), while tumor cells needed longer to detach (>5mins). Using selective trypsinization, we 
were able to isolate primary cell culture that predominantly contains mesothelial cells from tumor 
cells.  
To authenticate the cell lines to patients, DNA finger printing was determined with PowerPlex 21 
PCR Kit (Fitchburg, WI, USA), including 21 loci D1S1656, D2S1338, D3S1358, D5S818, 
D6S1043, D7S820, D8S1179, D12S391, D13S317, D16S539, D18S51, D19S433, D21S11, 
Amelogenin, CSF1PO, FGA, Penta D, Penta E, TH01, TPOX,  and vWA [14] and compared to 
that of the germline DNA.  
2.2. Extraction of DNA and RNA and cDNA synthesis 
DNA and RNA were extracted with AllPrep DNA/RNA Mini Kit (QIAGEN, Venlo, The 
Netherlands). DNA from formalin-fixed, paraffin-embedded (FFPE) tissue and blood samples 
was isolated using QIAamp DNA FFPE Tissue Kit (QIAGEN) and QIAamp DNA Mini Kit 
(QIAGEN). The quantity was determined by measuring the absorbance at 260/280 nm with 
Nanodrop 1000 (Thermo Fisher Scientific, Massachusetts, USA) and the quality of RNA was 
controlled using Agilent RNA 6000 Nano Kit (Agilent Technologies, CA, USA) and Agilent 
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2100 Bioanalyzer (Agilent Technologies). Samples with an RNA Integrity Number >8 were 
further processed for RNA sequencing. cDNA was synthesized with Omniscript RT Kit (Qiagen).  
2.3. Detection of mutations in the coding region of TP53, KRAS and BRCA1/2
Alterations in the coding regions of TP53 and KRAS genes were examined by Sanger sequencing. 
For TP53, three DNA fragments C0 (sense: 5’-TGCTTTCCACGACGGTGAC-3’; antisense: 5’-
AGCAGCCTCTGGCATTCTG-3’), C1 (sense; 5’-CCTCCTCAGCATCTTATC-3’, antisense: 
5’-AAGAAGTGGAGAATGTCAG-3’)  and C2 (sense: 5’-CCAAGCAATGGATGATT-3’; 
antisense: 5’-TAGTGGATGGTGGTACAGTC-3’) covering exon 1-4, 4-7 and 6-11, were 
amplified with annealing temperatures of 55°C, 50°C and 52°C, respectively. For KRAS, one 
single fragment covering the whole coding region (sense: 5’-ATTTCGGACTGGGAGCGAG-3’; 
antisense: 5’-GCATCATCAACACCCAGATTAC-3’) was amplified with an annealing 
temperature of 60°C with cDNA samples. PCR was performed with MangoMix (Bioline Reagent 
Ltd, London, UK) with 40 cycles of 30 sec at 94°C, 30 sec at the corresponding annealing 
temperature, and 30 sec at 72°C. The reactions were preceded with a 10 min denaturation step 
and an extension at 72°C for 10min. Mutations in the BRCA1 and BRCA2 coding regions were 
detected using TruSeq Custom Amplicon Design - AFP2, TruSeq CustomAmplicon Index Kit 
and Reagent Kit v2 (300cycles) and Illumina MiSeq System (Illumina; Inc., CA, USA). Once an 
alteration was found, it was verified with DNA or cDNA samples and confirmed in cell lines at 
different passages by Sanger sequencing.   
2.4. Measurement of mutant DNA proportion by allele specific digital droplet PCR (ddPCR) 
Allele specific ddPCR systems were designed to detect the absolute copy numbers of wild type 
and mutant TP53 and KRAS in DNA samples. Primers and probes are shown in Supplementary 
Table S4. PCR was performed using ddPCR Supermix for Probes (Bio-Rad Laboratories, Inc., 
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CA, USA) according the manufacturer’s instruction. Signals were detected by QX200 Droplet 
Digital PCR System (Bio-Rad Laboratories, Inc.). We used these systems to determine the tumor 
cell proportion in cell culture. Additionally, we performed these assays for cell lines at higher 
passages to ensure that all cells harbored their specific mutations. 
2.5 Low coverage whole genome sequencing and RNA-sequencing and annotation 
The methods were described in detail previously [11]. 
2.6. Determination of DNA copy number 
DNA copy number of TP53 and BRCA1/2 were detected with the corresponding PrimPCR 
ddPCR Copy Number Assays (dHsaCP1000586, dHsaCP2500367, dHsaCP2500368, 
respectively, Bio-Rad, CA, USA) with EIF2C1 (dHsaCP2500349) as reference gene following 
the manufacturer’s instruction (Bio-Rad Laboratories, Inc.). DNA from a healthy individual was 
used as a control. 
2.7. Unsupervised clustering 
RNA sequencing data includes 63 samples from 33 cell lines with one line 17066 excluded 
because of bad quality of sequencing results. Euclidean distance clustering was performed on the 
EDA normalized data using the top 10% of the expressed genes ranked by their standard 
deviation across the cohort. 
2.8. Analyses of specific gene expression 
Since cell lines with low passages had higher possibility to contain other types of cells, some of 
the samples were excluded according to the results of unsupervised clustering (indicated in 
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Figure 1). Mean expression was used for cell lines with more than one measurements at higher 
passages.  
2.9. In vitro carboplatin sensitivity test 
Chemo-sensitivity was measured by MTT assay using EZ4U-kit following the manufacturer’s 
instructions (Biomedica, New Hampshire, USA). 7x103 cells per well were seeded in 96-well 
plates (Costar, Corning Incorporated, USA) and incubated with carboplatin (Accord Healthcare, 
North Harrow, UK) in triplicate at 37°C and 5% CO2 for 96 h. At least three independent 
experiments were performed for each cell line. IC50 values were calculated using a non-linear 
dose-response curve with sigmoidal fit of logarithmic mean across the triplets of each assay by 
GraphPad Prism 5.00 for Windows (GraphPad Software, San Diego, CA, USA; 
www.graphpad.com). Carboplatin concentrations ranging from 100μg/ml (270M) to 0.4μg/ml 
(1.08μM) with 1:2 serial dilution between them were used in the initial test. We chose this range 
of concentrations, as the plasma peak value of carboplatin used for patients is around 300μM. If 
the cells showed borderline values of sensitivity, higher or lower concentrations were included in 
additional tests.  
2.10. Comparison of gene expression in two different groups of cell lines 
We compared the gene expression in tumor cells established before and after exposing to 
carboplatin-based therapy and tumors with or without wild-type BRCA1/2. For the latter, means 
were calculated in case more than one cell line was established from the same patient.  The 
nbinomTest function of the DEseq R package was used after normalization for the identification 
of differentially expressed transcripts [15]. p-values were adjusted using Benjamini Hochberg 
methods thus controlling the false discovery rate (FDR). Transcripts with an FDR<5%, a fold-
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change value > |5|, and read counts > 50 in the group showing higher read counts were considered 
as relevant.  
2.11. Selection of potential tumor specific antigens 
We selected genes coding for potential tumor specific antigens mainly from four sub-groups: (i) 
Cancer-testis like antigens (CTA); (ii) Differentiation antigens; (iii) Oncofetal antigens including 
-fetoprotein, carcinoembryonic antigen (CEA), trophoblast glycoprotein, onco-trophoblast, and 
solid tumor associated glycoprotein; (iv) Over-expressed antigens, mainly based on the 
information provided by Even-Desrumeaux et al. [16, 17]. Particularly, for CTAs, we referred the 
118 genes described as “testis-selective” or “testis restricted” in the CTDatabase maintained by 
The Ludwig Institute for Cancer Research (http://www.cta.lncc.br/). 
2.12. Measurement of PRAME gene expression by RT-qPCR 
TaqMan Assay Gene Expression Hs01022301_m1 was used to measure the PRAME expression 
in cell lines according to manufacturer’s instructions. A cell line with relative high expression of 
PRAME (according to RNA sequencing data) was used to make a dilution series to generate a 
standard curve. Relative expression values were calculated in fold of the standard samples. Cell 
line data were median-normalized for comparison of RT-qPCR results with RNA sequencing 
results. 
  
2.13. Immunohistochemistry staining and immunofluorescent staining 
Immunohistochemistry was performed as described previously [11]. Antibodies against PRAME 
(PA5-13679; Thermo Fischer Scientific) and EpCAM (ab32329; abcam, Cambridge, UK) was 
diluted at 1:400 and 1:500 in Dako Antibody-Diluent (Agilent Technologies), respectively, and 
incubated with the slides at 4°C overnight.  Immunofluorescent staining (IF) was performed on 
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slides pretreated with adhesion substance (Paul Marienfeld GmbH & Co. KG, Lauda-
Königshofen, Germany). 50000 cells were subjected to each well on the slides following the 
instruction of the manufacturer, dried and fixed in 4% paraformaldehyde. The slides were treated 
with 0.5% Triton X-100 in PBS, washed 3 times with PBS, each time for 3 mins and incubated 
with Dako Ultra Vision Block (Thermo Fischer Scientific) for 7 min at RT followed by washing 
in PBS-Tween 20 twice, each for 3 min. The PRAME antibody was diluted at 1:100 in Dako 
Antibody-Diluent and incubated at 4°C overnight. Alexa Fluor 488 goat anti-Rabbit IgG (Thermo 
Fisher Scientific) was diluted 1:500 in Dako Antibody-Diluent and incubated for an hour at RT. 
DAPI staining was performed with standard protocol and the slides were mounted with 
Fluoromount-G (Southern Biotech, Birmingham, USA). 
2.14. Data and materials availability  
We are willing to distribute any materials (cell lines), data (RNA sequencing, low coverage 
sequencing, patient clinicopathological data) and protocols in the published experiments to 
qualified researchers for their own use upon reasonable request.  
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3. Results 
3.1. HGSOC cell lines and patients 
34 tumor cell lines from ascites, tumor tissue and pleural fluid from 23 patients with HGSOC 
were established (Table 1). Part of the results regarding seven of them was reported previously 
[11].  
From five patients (P3, P9, P12, P16, P17), we established more than one cell line from tumor 
material collected either from different locations or at different time points (Table 1). We also 
cultivated primary mesothelial cells from the ascites of eight patients, which could be passaged 
approximately 10 times until they underwent senescence or died. Their cell type identity was 
confirmed by pathologists (Supplementary Figure S1). In addition, they expressed very high level 
of CALB2 (>4000 read counts), which is a marker for mesothelial cells, and had little or no 
expression of EPCAM (26-692 read counts). This was in contrast to tumor cells, which had very 
high EPCAM expression (1781-47851 read counts) and no or very low CALB2 expression (0-304 
read counts). Furthermore, they had wild-type TP53, while their counterpart tumor cells harbored 
mutant TP53 (see also 3.2).  
All cell lines were authenticated to be from the corresponding patients by DNA finger printing 
analyses (Supplementary Table S1). The purity of the tumor cells was determined by allele 
specific digital droplet PCR systems measuring the proportions of tumor specific mutant TP53 or
KRAS DNA copies. All cell lines have been passaged over 30 times. 
3.2. The cell lines are stable experimental models for HGSOC   
In all cell lines except one, unique TP53 alterations affecting the transcripts were detected and no 
wild type allele could be found (Table 1, Supplementary Table S2). The alterations in mRNA 
were derived either directly from DNA or from intronic changes leading to variant splicing. p53 
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protein was truncated with variant C-terminals or affected by substitution or deletion of amino 
acids. All TP53 alterations were located in the DNA binding domain except in patients P4 and 
P6, whose tumors had alterations in the oligomerization domain (Supplementary Figure S2). 
Germline BRCA1 and BRCA2 mutations were detected in one (P6) and three (P5, P7, P11) of 
these cell lines, respectively, all losing wild-type alleles in tumor cells. Patient P17 presented 
with a somatic BRCA2 mutation with loss of heterozygosity. In addition, P15 had a heterozygous 
germline BRCA2 mutation, which was retained in the corresponding tumor. The tumor cells from 
P18 harbored a heterozygous somatic BRCA2 mutation. The only TP53 wild-type cell line 8540 
had a heterozygous KRAS mutation. We re-examined two FFPE blocks and confirmed the high 
grade serous histological type (Supplementary Figure S3).  The genetic profile of the FFPE 
samples, the cell lines and the patient blood sample were confirmed by DNA finger printing 
analyses. Both mutant and wild-type DNA copies of KRAS were detected in DNA samples 
isolated from FFPE sections by allele specific ddPCR. Sanger Sequencing confirmed that the 
status of TP53, BRCA1/2 and KRAS mutations was unchanged in different cell lines established 
from the same patients and remained stable through passaging.  
Low coverage sequencing revealed that all TP53 mutant cell lines had a high incidence of copy 
number alterations (CNA) compared to their corresponding germline DNA, e.g. P_16099B. The 
TP53 wild-type and KRAS mutant cell line P8_8540 had less CNA than the TP53 mutant cell 
lines (Supplementary Figure S4). Nevertheless, cell lines established from the same patients 
presented similar pattern of CNA. 
Unsupervised clustering of gene expression profiles of 63 RNA samples including cell lines with 
different passages (Figure 1) revealed that (i) the primary mesothelial cell cultures had different 
expression profiles than all tumor cell lines; (ii) different passages of the same tumor cell lines 
had very similar expression profiles; (iii) cell lines derived from the same patient had the most 
similar expression profiles, regardless of whether they were derived from different locations (e.g. 
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Patient P17) or whether they were established at different time points of disease progression (e.g. 
Patients P3, P9, and P12). 
3.3. Cell cycle pathway is the determinant for tumorigenesis and tumor progression  
We first examined genes, whose transcription is directly regulated by p53 and found that major 
genes controlling cell cycle arrest, apoptosis, survival and senescence CDKN1A (p21), BAX, 
TIGAR, PAI1 and MDM2 were all down-regulated in the TP53 mutant tumor cells in comparison 
with the TP53 wild type cell line 8540 and the mesothelial cells (Figure 2A-E). Furthermore, 
cyclins controlling the cell cycle restraint points cyclin D1 (CCND1), E1 (CCNE1), A1 (CCNA1) 
and B2 (CCNB2) were overexpressed in all tumor cells. No obvious differences could be 
observed regarding the expression of other cyclins (Figure 2F-O). The KRAS mutant cell line 
8540 showed additional higher expression of cyclin D2 (CCND2) (Figure 2G) in comparison to 
all other cell lines. 
3.4. Response to carboplatin in vitro and in vivo
Most of the tumor cell lines showed lower IC50 values for carboplatin than the primary 
mesothelial cell cultures, indicating that carboplatin preferentially kills tumor cells (Figure 3A). 
A few cell lines showed very high values (8684, 18483). Different cell lines from the same 
patients presented different pattern of changes of the IC50 values. Some became more resistant in 
later established lines (e.g. 15233_nov was collected 12 months later than 13363; 17249 was 
collected 20 days later than 17142), while others showed the opposite change and became more 
sensitive (e.g. the 6 cell lines from P9 were derived from ascites isolated over a total interval of 
12 months; EK_R1 was taken 6 months later then 8714 and 17457). Cell lines from P17 were 
established from ascites (17480) and tumor tissues (8715, 8716) at primary diagnosis and showed 
similar sensitivities. 
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Seven patients had no residual tumors after primary surgery, presented a clinical complete 
remission at the completion of the first line treatment, and then developed recurrent disease. 
From six of these patients, we established cell lines from primary tumor material. By comparing 
the IC50 value with the progression free interval (PFI), no correlation could be observed between 
the two parameters (Figure 3B). 
We further examined clinical data of all patients (Supplementary Figure S5). 10 patients had at 
least one recurrence (red colored) and received at least 2 lines of platinum-based treatment. The 
CA-125 dropped upon the treatment of platinum-based drug by almost all cycles with a few 
exceptions during the whole treatment.  
In addition, we did not observe particularly low IC50 values of the cell lines with BRCA1 or 
BRCA2 mutations (Figure 3A). By comparing gene expression profiles of the cell lines from the 5 
patients with only mutant BRCA1/2 and the remaining 18 patients with at least one wild type 
BRCA1/2 allele, we did not find any differentially expressed genes between the two groups, even 
after lowering the fold change (FC) threshold to 2.  
Moreover, we compared gene expression profiles of cell lines with and without exposure to 
chemotherapy treatment and we found that only one gene NBL1 was overexpressed in the 
exposed cells and eight transcripts were overexpressed in the naive cells, all being non-coding 
RNA genes (RP5-1114G22.2, FAM103A2P, OVAAL, RP11-527N22.1, DDX11L9, RP11-
438N16.1, H19, AC004540.4). By lowering the fold change (FC) threshold from 5 to 2, the 
results were unchanged.  
3.6. PRAME and the estrogen receptor (ER) are potential therapeutic targets for HGSOC 
We selected a panel of tumor associated antigens including cancer-testis like antigens, 
differentiation antigens, oncofetal antigens and some known cancer related overexpressed 
antigens [16, 17] and examined their expression in tumor cell lines in comparison with the five 
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mesothelial cell cultures. Most of the genes had no or little expression in all samples 
(Supplementary Table S3; AFP; BAGE2; CEACAM3, 4, 5, 7, 8, 16, 18, 20, 21; CEACAMP1, 2, 
5, 7, 8, 9, 11; MAGEA3, A12, B2, C1; MUC2, 3A, 5AC, 12, 13, 19; PSG1; TEX15; TLX1, 2, 3). 
Some had comparable high expression in both tumor cells as well as in the mesothelial cells (e.g. 
EGFR, ERBB2, MGAT5, MUC16, SPAG9, TPBG, TSPYL1). 27 genes were found to be higher 
expressed in tumor cells than in mesothelial cells, but with different prevalence. Three had low 
expression in tumors and high expression in mesothelial cells and 16 had rather low prevalence 
of highly expressing tumors (Table 2). Four genes MAGEA4, MAGEA11, MUC4 and SPAG1 had 
high expression in less than 50% of the samples. Four genes had high prevalence in all tumors, 
among which FOLR1, MUC1 and MUC20 are expressed in multiple organs/tissues, such as 
kidney, salivary gland, lung, or fallopian tube (https://www.proteinatlas.org; 
https://www.genecards.org). PRAME was highly expressed in 94% of all tumor cell lines but not 
in the mesothelial cells. It was reported to be only expressed in testis tissue and to a lesser extent 
in ovary [18, 19]. PRAME was not expressed in 8540 and had a very low expression in 18605 
(Figure 4A). Evaluation of the RNA sequencing data with RT-qPCR confirmed that PRAME
indeed had very high expression in 31/33 cell lines and was not expressed in mesothelial cells 
and fibroblasts (Figure 4B). By examining the RNA sequencing data from 66 matched primary 
and recurrent HGSOC tumor tissues from a previous study [13], high expression of PRAME was 
confirmed (Figure 4C) in almost all tumors. A few samples showed lower expression in both 
samples or in one of the matched samples (Figure 4D).  
Immunohistochemistry and immunofluorescent staining of the corresponding tumor tissues 
showed that PRAME protein was expressed in nucleus, cytoplasm and at the membrane of the 
tumor cells (Figure 5).  
Additionally, the gene coding for ER, ESR1 showed higher expression in TP53 mutant tumor 
cells and was low in 8540 and the mesothelial cells (Figure 2P). There was no or very low 
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expression of the progesterone receptor (PGR) in TP53 mutant tumor cells (read counts: 
median=1, q1=0, q3=23) and 8540 (read count: 3).   
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We successfully established 34 patient-derived HGSOC cell lines and characterized them at the 
cellular and molecular level. With these new cell lines, we provide useful models to the scientific 
community to study the tumorigenesis and progression of HGSOC. Particularly, we demonstrated 
that a cancer-testis antigen PRAME and the ER could serve as therapeutic targets. The 
experimental results did not show acquired resistance of recurrent tumors, which was in line with 
the clinical observations. Finally, we presented that all HGSOC had no or very low CDKN1A
(p21) expression due to loss of wild type TP53.  
Since Domcke et al. [5] pointed out that many of the ovarian cancer cell lines historically used 
for research are unlikely to be of high grade serous origin, great efforts have been paid to 
establish patient-derived new models including cell lines and patient-derived xenografts. The 
current study presents 34 new cell line models, analyzed at the level of transcriptomics, CNV 
profile and mutations of TP53, BRCA1/2 and KRAS genes that are linked to clinicopathological 
information, treatment, and response of the patients.  
Despite extensive research and the introduction of some additional therapeutic options such as 
Bevacizumab, ovarian cancer remains a cancer with poor prognosis [20]. Carboplatin is still the 
gold standard treatment for HGSOC, which kills cells nonspecifically and is highly toxic [3]. So 
far, identifying tumor specific targets has been a big challenge for the scientific community. 
Some proteins, such as the Wilms tumor protein, could not serve as an optimal target, since they 
are not only highly expressed in ovarian cancer cells, but also in the mesothelium [21]. An ideal 
therapeutic target should have a homogeneous expression in tumors and no or minimal 
expression in normal tissues [16]. Thus, we examined the expression levels of a panel of genes 
coding for possible tumor associated antigens and some membrane proteins. Four genes, MUC1, 
MUC20, FOLR1 and PRAME with high expression levels and high prevalence across all tumor 
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cell lines were identified. Among these four genes, MUC1 is expressed in almost all epithelial 
tissues and in some hematopoietic cells [22] and MUC20 was detected in multiple organs, such as 
kidney, lung, liver, and the digestion system [23]. Expression of FOLR1 was also found in 
normal tissues such as kidney, bladder, salivary glands, lung and some cells of the nerve system 
[24]. In contrast to the multiple tissue expression of these three genes, PRAME expression is only 
found in normal testis tissues and to a lesser extent in the ovary. Since the ovaries of the HGSOC 
patients were affected by tumors and are usually removed during surgery, targeting PRAME 
would not affect normal tissues. Our results also showed that PRAME was not expressed in 
mesothelial cells lining the peritoneal cavity and in fibroblasts, which makes PRAME an optimal 
target for therapy development. 
PRAME, the preferentially expressed antigen in melanoma gene, was first detected in a mRNA 
study of human testis [25]. It codes a membrane-bound protein and triggers autologous cytotoxic 
T cell-mediated immune responses, presumably through retinoic acid signaling [18, 26, 27]. Its 
overexpression in several solid tumors, such as melanoma [28], breast cancer [19], and sarcomas 
[29, 30] as well as in hematological malignancies [27] makes it an interesting therapeutic target. 
Recent studies using recombinant PRAME and an immunostimulant demonstrated a cellular 
immune response in patients in addition to safety [31, 32]. Furthermore, a polyclonal antibody 
was produced against PRAME and was shown to bind recombinant PRAME ex vivo as well as 
different cells in vitro [33]. In ovarian cancer, PRAME was found to be frequently expressed in 
epithelial cancer at both mRNA and protein levels, which was regulated by DNA methylation 
[34], and to have prognostic value for stage III serous cancer [35-37] . Further investigation will 
be needed to understand the expression activation and functions of PRAME in TP53 mutant 
HGSOC to provide the basis for drug development, for which the new patient-derived cell lines 
presented in this study are ideal models. 
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Patients with serous ovarian cancer that have positive hormonal receptor status were shown to 
have worse survival than those with negative receptor status [38]. Since the ovary produces 
estrogen, which could promote cell growth upon binding to its receptor ER, we also examined the 
expression level of ESR1 gene and found a high expression of this gene in most of the TP53
mutant tumor cell lines. Endocrine therapy was shown to bring benefits to patients with advanced 
epithelial ovarian cancer [39], probably by blocking the ESR1 promoted tumor cell growth. Even 
though the effect was not specified to HGSOC, it is worth further investigation in a well-defined 
population. Using our cell line models, the transcriptional regulation of ESR1 could be further 
studied. 
Originally, platinum resistance was defined for tumors, which recur within 6 months after 
completing first line therapy [40]. This concept of clinical resistance, however, does not 
necessarily associate with the response of tumor cells to drug. Other possible reasons for a rapid 
recurrence of tumors could be the quick exponential proliferation or/and higher number of living 
tumor cells after therapy due to poor accessibility of the drug. This clinical definition of 
resistance was equaled to a cellular resistance in 2011 for ovarian cancer [41], while the 
hypotheses of acquired resistance and the evolution of resistance were proposed. Our cell line 
models showed that recurrent tumor cells did not become more “resistant” to carboplatin than 
their primary counterparts, which was in accordance with patient response presented by clinical 
data, suggesting that recurrent tumors resemble their primary ancestors. Molecular analyses of 
their transcriptional profiling and CNV profiles further suggest the similarities of the primary and 
recurrent tumor cells. Nevertheless, the current study included a small cohort of 23 patients and 
establishing cell lines might involve selections of tumors with distinct molecular characteristics. 
Thus, evaluation in a larger cohort of patients will be needed to clarify this issue. 
By examining genes, whose transcription is directly regulated by p53 [42], a clear down 
regulation was observed for the key genes, which regulate the cell cycle (p21, CNKN1A), 
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apoptosis (BAX), senescence (PAI1) [43]  and survival (TIGAR) [44] in all TP53 mutant cell 
lines, indicating that the loss of wild-type p53 functions is the major driving force of tumor cell 
progression. We also observed higher expression of genes coding for cyclins D1 (CCND1), E1 
(CCNE1), A1 (CCNA1) and B2 (CCNB2), demonstrating that TP53 mutant tumor cells had a 
high endogenous level of all cyclins needed to pass the G1/S and G2/M restriction points. 
Synchronized with the down-regulation of p21, the inhibitor of the cyclin and the cyclin-
dependent kinase complexes, tumor cells lost the restraints in their cell cycle and were directed to 
proliferation. Our data suggest that loss of the wild-type TP53 is not only the reason for 
tumorigenesis but also the driver of tumor progression. Although well established, we confirmed 
in the current study that all these cellular processes are common for all TP53 mutant HGSOC. It 
is important to emphasize on the determinant role of cell cycle control in HGSOC, so that efforts 
could be directed towards the main reason of disease progression in the development of new 
therapies.  
Taken together, we (i) established and molecularly analyzed 34 cell lines from 23 HGSOC 
patients, (ii) showed that loss of TP53 wild type was the main driving force of tumorigenesis and 
tumor progression, and (iii) identified PRAME as a potential therapeutic target. The cell line 
models can be applied for therapy development in addition to the investigation of molecular 
mechanisms in disease progression.  
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ENSG00000079385 CEACAM1 X 
ENSG00000186567 CEACAM19 X 
ENSG00000197279 ZNF165 X 
ENSG00000104327 CALB1 X 
ENSG00000086548 CEACAM6 X 
ENSG00000198681 MAGEA1 X 
ENSG00000197172 MAGEA6 X 
ENSG00000124260 MAGEA10 X 
ENSG00000046774 MAGEC2 X 
ENSG00000117983 MUC5B X 
ENSG00000184956 MUC6 X 
ENSG00000169550 MUC15 X 
ENSG00000185664 PMEL X 
ENSG00000183206 POTEC X 
ENSG00000196604 POTEF X 
ENSG00000196834 POTEI X 
ENSG00000181433 SAGE1 X 
ENSG00000155761 SPAG17 X 
ENSG00000241697 TMEFF1 X 
ENSG00000147381 MAGEA4 X 
ENSG00000185247 MAGEA11 X 
ENSG00000145113 MUC4 X 
ENSG00000104450 SPAG1 X 
ENSG00000110195 FOLR1 X 
ENSG00000185499 MUC1 X 
ENSG00000176945 MUC20 X 
ENSG00000185686 PRAME X 
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Figure 1. Unsupervised clustering of 63 samples. M in the color column indicates five 
primary cell cultures mostly including mesothelial cells. The number in the colored frames 
indicates the patient number. Passages of the cell lines were indicated after “#”. Asterisks 
indicate the samples, which are excluded for further analyses. The close brackets indicate the 
samples, from which the means are calculated for further analyses.  
Figure 2. Expression of determinant genes in different groups of cells. Y-axis indicates the 
gene expression values obtained from RNA sequencing (read counts). M, T and 8540 
represent primary mesothelial cell cultures, tumor cell lines with mutant TP53 and cell line 
8540 with wild-type TP53 and a KRAS mutation, respectively. Box includes all values 
between quartile 1 to quartile 3. By “T”, the 90th and the 10th percentile are shown and the 
outliers are indicated by dots. By “M”, the individual values are shown in dots and the mean 
value is indicated by a bar.  
Figure 3. Sensitivity of the cell lines to carboplatin. A. IC50 values obtained by in vitro
chemosensitivity tests. The left cluster of cell lines are those established only once from one 
patient; each of the five clusters in the middle includes cell lines established from the same 
patient. The cluster at the right contains five primary mesothelial cell cultures. The cycle 
indicates the cell line with BRCA1 mutation, while the dots indicate the lines with BRCA2
mutations. The asterisks indicate the lines, which were derived from tumor material already 
exposed to carboplatin treatment. The values are shown as mean ± SD. P indicates the patient 
number. B. Comparison of the IC50 values with PFI of the corresponding patients. All patients 
in this selected group had no macroscopically visible residual tumor after surgery, had clinical 
complete remission after completing the first line treatment and had developed recurrent 
disease. The corresponding cell lines were derived from tumor material collected at primary 
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diagnosis. The cell lines are arranged in the way with decreased IC50 values from top to 
bottom. 
Figure 4. PRAME gene expression. HGSOC: high grade serous ovarian cancer cell lines, 
ordered as explained in Figure 3; M: mesothelial cell cultures; F: cell cultures containing 
mainly fibroblasts; OVCAR3 (NIH:OVCAR-3): an ovarian cancer cell line purchased from 
ATCC (ATCC HTB-161). 4A. PRAME expression in cell lines measured by RNA 
sequencing. 4B. Relative PRAME expression measured by RT-qPCR. 4C. P AME expression 
of 66 pairs of matched primary and recurrent HGSOC tumor tissues measured by RNA 
sequencing. The bars present q1, median and q3; 4D. Correlation of PRAME expression in 
matched primary and recurrent samples. PRAME expression obtained from RNA sequencing 
in the 66 primary tumors are plotted against the corresponding recurrent ones. The triangles 
indicate two pairs of tumors both with low PRAME expression; the rhombus indicates a pair 
with low PRAME in recurrent tumor and higher value in primary sample; the squares indicate 
two pairs with low values in primary samples and high values in recurrent tumors.  
Figure 5. PRAME protein expression in FFPE samples. The coding of the patients is indicated 
on top of each picture. The scale is indicated in the first picture on top-left with a single 
exception of HE staining of tumors from P8, which showed a clear HGSOC histologic type. 
The cell line derived from this tumor has wild-type TP53 and a KRAS mutation, which is 
considered to be typical for low-grade serous cancer. 
Supplemental Figure S1. Morphology of the cells. Only the newly established cell lines are 
shown. Primary mesothelial cell cultures presented similar morphology, which is represented 
by P7_14433_2. 
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Supplemental Figure S2. Putative p53 protein sequences predicted according to the cDNA 
sequencing results. The number above each block indicate the codon number of a wild-type 
p53 and the background colors indicate different p53 domains (transactivation domain: 1-63; 
proline-rich region: 64-92; DNA binding domain: 102-292; tetramerization domain: 320-355 
and finally the regulatory domain at 356-393). The number of the patients is indicated at the 
left side. Protein changes are indicated in green, red and turquoise for deletion (“ ”), missense 
mutation and truncated protein sequences, respectively. The asterisk indicates a stop codon. 
Supplementary Figure S3. Histology of the corresponding tumor of 8540. A and B: HE 
staining of two FFPE sections; C and D: IHC of EpCAM of the corresponding FFPE section 
of A and B, respectively.  
Supplemental Figure S4. Low-coverage sequencing plots of the newly established cell lines. 
The red dots indicate the individual LogR values per bin and the green lines indicate the 
segmented values as calculated by ASCAT v.2.0.7. 
Supplementary Figure 5. Follow-up and treatment information of the patients. Patient coding 
and cell lines are indicated at the top of each diagram. R0 indicates no macroscopically visible 
residual tumor, while R1 indicates residual tumors after surgery. Blue lines indicate treatment 
with platinum-based drugs, while grey lines other treatment including paclitaxel, doxorubicin, 
topotecan, or gemcitabine. Day “0” indicate the time point of primary surgery. For P15 and 
P19, no CA125 measurement was available. The horizontal green lines indicate the threshold 
value of CA 125 (35 U/mL). 
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Highlights
• We established 34 patient-derived HGSOC cell lines, which meets the urgent need; 
Particularly, we demonstrated that a cancer-testis antigen PRAME in addition to ER 
could serve as a therapeutic target; 
• Notably, the experimental results did not show any acquired resistance that is in line 
with the clinical observation; 
• Finally, we presented that all HGSOC had no or very low CDKN1A (p21) expression 
due to loss of wild type TP53, suggesting that loss of the cell cycle control is the 
determinant for tumorigenesis and progression. 
